U.S. markets closed

Organovo Holdings, Inc. (ONVO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.2100+0.2300 (+7.72%)
At close: 04:00PM EDT
3.2000 -0.01 (-0.31%)
After hours: 07:27PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close2.9800
Bid3.2000 x 1000
Ask3.2900 x 1100
Day's Range2.9600 - 3.2700
52 Week Range1.7100 - 8.3000
Avg. Volume96,096
Market Cap27.965M
Beta (5Y Monthly)1.10
PE Ratio (TTM)N/A
EPS (TTM)-1.3150
Earnings DateFeb 08, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for ONVO

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Organovo Holdings, Inc.
    ARWR: Raising target price to $27.00ARROWHEAD PHARMACEUTICALS IN has an Investment Rating of SELL; a target price of $27.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
    Fair Value
    Economic Moat
    last monthArgus Research
View more
  • Simply Wall St.

    We're Not Very Worried About Organovo Holdings' (NASDAQ:ONVO) Cash Burn Rate

    There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

  • GlobeNewswire

    Organovo Achieves 3D Tissue Model for Crohn’s Disease

    SAN DIEGO, May 17, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), a three-dimensional (3D) biology company focused on delivering scientific and medical breakthroughs using novel technologies including 3D bioprinting, today announces that it has successfully advanced its first inflammatory bowel disease (IBD) model to the next step of target discovery and validation for Crohn’s disease. Based on its internal data and scientific results, the company believes that its first IBD mo

  • Motley Fool

    Why Organovo Holdings, Inc. Stock Soared 49.7% This Week

    The company's licensing agreement with a Swedish company means an infusion of some much-needed cash for Organovo.